<SEC-DOCUMENT>0001104659-23-046294.txt : 20230417
<SEC-HEADER>0001104659-23-046294.hdr.sgml : 20230417
<ACCEPTANCE-DATETIME>20230417171427
ACCESSION NUMBER:		0001104659-23-046294
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20230417
DATE AS OF CHANGE:		20230417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-271296
		FILM NUMBER:		23824723

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tm2312861-1_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html>
  <head>
    <title>tm2312861-1_s3 - none - 3.8750395s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">As filed with the Securities and Exchange Commission on April&#160;17, 2023</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:1.2pt; text-align:right; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:2.7pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.7pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.21pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.21pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:9.2pt; text-align:center; width:541.31pt; line-height:17pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">UNITED STATES</font>
          <br >
          <font style="letter-spacing:-0.32pt;">SECURITIES AND EXCHANGE COMMISSION</font>
          <br >
          <font style="font-size:8.5pt;letter-spacing:-0.17pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:6.033pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 6.03333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.2pt; text-align:center; width:541.31pt; line-height:17.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">FORM S-3</font>
        </div>
        <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:9.5pt;font-style:italic;font-weight:bold;font-size:8.5pt;">
          <font style="font-style:normal;letter-spacing:-0.17pt;">REGISTRATION STATEMENT</font>
          <br >
          <font style="letter-spacing:-0.17pt;">UNDER </font>
          <br >
          <font style="letter-spacing:-0.17pt;">THE SECURITIES ACT OF 1933</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.17pt;"> </font>
        </div>
        <div style="margin-top:3.533pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 3.53333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.2pt; text-align:center; width:541.31pt; line-height:17.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">CARISMA THERAPEUTICS INC.</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:4.367pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 4.36666666666665pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.21pt; text-align:center; width:541.31pt; line-height:9pt;font-size:7.5pt;">
          <font style="letter-spacing:0.15pt;">(Exact name of registrant as specified in its charter) </font>
        </div>
        <table style="width:360.66pt;margin-left:90.33pt;margin-top:4.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
          <tr style="line-height:10.7pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:168.66pt;">
              <div style="text-align:center;font-weight:bold;font-size:8.5pt;">
                <font style="letter-spacing:-0.17pt;">Delaware</font>
              </div>
              <div style="margin-top:1.7pt; text-align:center; line-height:9pt;">
                <font style="letter-spacing:0.16pt;">(State or other jurisdiction of </font>
                <br >
                <font style="letter-spacing:0.16pt;">incorporation or organization)</font><font style="font-size:8.5pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180pt;">
              <div style="text-align:center;font-weight:bold;font-size:8.5pt;">
                <font style="letter-spacing:-0.17pt;">26-2025616</font>
              </div>
              <div style="margin-top:1.7pt; text-align:center; line-height:9pt;">
                <font style="letter-spacing:0.16pt;">(I.R.S. Employer </font>
                <br >
                <font style="letter-spacing:0.16pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.2pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.2pt; text-align:center; width:541.31pt; line-height:9pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">3675 Market Street, Suite 200</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Philadelphia, PA 19104</font>
          <br >
          <font style="letter-spacing:-0.16pt;">(267) 491-6422</font>
        </div>
        <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.16pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </font>
        </div>
        <div style="margin-top:3.7pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 3.70000000000002pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.2pt; text-align:center; width:541.31pt; line-height:9pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Steven Kelly </font>
          <br >
          <font style="letter-spacing:-0.16pt;">President and Chief Executive Officer </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Carisma Therapeutics Inc. </font>
          <br >
          <font style="letter-spacing:-0.16pt;">3675 Market Street, Suite 200 </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Philadelphia, PA 19104 </font>
          <br >
          <font style="letter-spacing:-0.16pt;">(267) 491-6422</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.16pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </font>
        </div>
        <div style="margin-top:3.7pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 3.70000000000005pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.2pt; text-align:center; width:541.31pt; line-height:9.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Copy to:</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:9pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Brian A. Johnson</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Wilmer Cutler Pickering Hale and Dorr LLP</font>
          <br >
          <font style="letter-spacing:-0.16pt;">7 World Trade Center</font>
          <br >
          <font style="letter-spacing:-0.16pt;">250 Greenwich Street </font>
          <br >
          <font style="letter-spacing:-0.16pt;">New York, New York 10007 </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Telephone: (212) 230-8800 </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Fax: (212) 230-8888</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:3.7pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 3.69999999999999pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:6.2pt; width:521.31pt; line-height:9.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.16pt;">Approximate date of commencement of proposed sale to the public</font><font style="letter-spacing:0.16pt;">: From time to time after this registration statement becomes effective. </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:&#160;&#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: &#9746; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </font>
        </div>
        <table style="width:501.31pt;height:35.1800000000001pt;margin-left:20pt;margin-top:4.5pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.98000000000002pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.61pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Large accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.16pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.61pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.16pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98000000000002pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Non-accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.16pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Smaller reporting company</font>
                <br >
              </div>
              <div style=" line-height:8pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.16pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98000000000002pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.66pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:244.65pt;white-space:normal;">
              <div style=" float:left; line-height:8pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Emerging growth company</font>
                <br >
              </div>
              <div style=" line-height:8pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.16pt;">&#9744;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10.8pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </font>
        </div>
        <div style="margin-top:3.8pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 3.79999999999995pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:6.31pt; width:541.31pt; line-height:9pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.</font>
        </div>
        <div style="margin-top:4.8pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 4.80000000000007pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.3pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.29999999999995pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow-x:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.83pt;left:48.66pt;height:30.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">
          <font style="letter-spacing:-0.08pt;">The information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and the selling stockholders named in this prospectus are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:87.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;color:#FC0014;">
          <font style="letter-spacing:-0.2pt;">Subject to completion, dated April&#160;17, 2023</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.11pt; text-align:center; width:456pt;">
          <img src="lg_carismatherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_carismatherapeutics-4c.jpg]" height="79" width="289" >
        </div>
        <div style="margin-top:13.92pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">3,730,608 SHARES</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:9.62pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">COMMON STOCK</font>
        </div>
        <div style="margin-top:15.953pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:10.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus relates to the resale of up to 3,730,608 shares of common stock of Carisma Therapeutics Inc. by the selling stockholders identified in this prospectus. We are registering these shares on behalf of the selling stockholders, to be offered and sold by them from time to time. We will not receive any proceeds from the sale of the shares offered by this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have agreed, pursuant to a Registration Rights Agreement that we entered into with the selling stockholders, to bear all of the expenses incurred in connection with the registration of these shares. The selling stockholders will pay or assume underwriting discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of shares of our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders identified in this prospectus, or their transferees, pledgees, donees or other successors-in-interest, may offer the shares from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. For additional information on the methods of sale that may be used by the selling stockholders, see the section entitled &#8220;Plan of Distribution&#8221; in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus, including the documents incorporated by reference in this prospectus, and any amendments or supplements carefully before you make an investment decision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;CARM.&#8221; On April&#160;14, 2023, the closing sale price of our common stock on the Nasdaq Global Market was $3.56 per share. You are urged to obtain current market quotations for our common stock. </font>
        </div>
        <div style="margin-top:16.62pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:10.11pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our common stock involves significant risks. See the information included under &#8220;Risk Factors&#8221; on page <a href="#tRIFA">4</a> of this prospectus and under similar headings in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase shares of our common stock.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:16.62pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:10.11pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:16.61pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:140.98pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The date of this prospectus is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2023</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:266.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:188.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">1</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHOF">3</a></font> <a href="#tTHOF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">4</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tFOST"><font style="letter-spacing:0.2pt;">FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tFOST">5</a></font> <a href="#tFOST"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">7</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSEST"><font style="letter-spacing:0.2pt;">SELLING STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSEST">8</a></font> <a href="#tSEST"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">14</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">17</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">19</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">19</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">20</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIBR"><font style="letter-spacing:0.2pt;">INCORPORATION BY REFERENCE</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIBR">20</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information contained in or incorporated by reference in this prospectus. We have not authorized anyone to provide you with different or additional information. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. Our business, financial condition, results of operations and prospects may have changed materially since such date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the context otherwise indicates, references in this prospectus to the &#8220;Company,&#8221; &#8220;Carisma,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer, collectively, to Carisma Therapeutics Inc., a Delaware corporation, and its consolidated subsidiaries.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights, and is qualified in its entirety by, the more detailed information included elsewhere in this prospectus or incorporated by reference in this prospectus. This summary does not contain all of the information that you should consider before investing in our common stock. You should read and carefully consider the entire prospectus, including the information incorporated by reference in the prospectus, especially the risks of investing in our common stock discussed in the &#8220;Risk Factors&#8221; section.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Carisma Therapeutics Inc.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Carisma is a clinical stage cell therapy company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. Macrophages and monocytes are part of the innate immune system and can detect and degrade harmful substances through a process referred to as phagocytosis, in which the harmful substance is engulfed and destroyed and in turn leads to the activation of a broad immune response. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">To harness the powerful immunologic functions of macrophages against cancer, we have developed a proprietary Chimeric Antigen Receptor Macrophage, or CAR-M, platform technology. Chimeric antigen receptors, or CARs, are synthetically engineered receptors that are designed to bestow immune cells with the ability to target specific antigens on the surface of cancer cells. By introducing CARs into macrophage and monocyte cells, we aim to redirect their potent innate immune functions against cancer. Our CAR-M platform technology incorporates proprietary tumor targeting constructs vectors to deliver CARs to macrophages and monocytes and novel manufacturing processes. Our CAR-M therapeutics are designed to infiltrate the solid tumor microenvironment, kill cancer cells via targeted phagocytosis, and activate other immune cells, such as T-cells, to initiate a robust anti-tumor immune response. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our lead product candidate CT-0508, the first CAR-M to be evaluated in a human clinical trial, is an </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> autologous cell therapy product candidate, wherein immune cells from blood drawn from a patient are engineered outside of the body and reinfused into the same patient. CT-0508 is intended to treat solid tumors that overexpress HER2, a protein that is overexpressed on the surface of a variety of solid tumors, including breast cancer, gastric cancer, esophageal cancer, salivary gland cancer, and numerous others. Beyond CT-0508, we have a broad pipeline of cell therapy assets in various stages of pre-clinical development. In addition to the development of </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> CAR-M cell therapies, we are also developing in vivo CAR-M gene therapies, wherein immune cells are directly engineered within the patient&#8217;s body. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated under the laws of the state of Delaware on February&#160;25, 2008 under the name NewCo LS14, Inc. We subsequently changed our name to DeNovo Therapeutics, Inc. in September&#160;2008, to Eleven Biotherapeutics, Inc. in February&#160;2010, to Sesen Bio, Inc. in May&#160;2018 and to Carisma Therapeutics Inc. in March&#160;2023, in connection with the completion of the Merger (as defined below). </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 3675 Market Street, Suite 200, Philadelphia, Pennsylvania 19104, and our telephone number is (267) 491-6422. Our website address is www.carismatx.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Private Placement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On March&#160;7, 2023, we completed a business combination in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of September&#160;20, 2022, as subsequently amended, by and among the Company, CTx Operations, Inc. (formerly CARISMA Therapeutics Inc.), or Legacy Carisma, and Seahawk Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, or Merger Sub, pursuant to which, among other matters, Merger Sub merged with and into Legacy Carisma, with Legacy Carisma continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, or the Merger. As of the effective time of the Merger, we changed our name from &#8220;Sesen </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; and the business conducted by the Company became primarily the business conducted by Legacy Carisma, as described above. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Immediately prior to the effective time of the Merger, Legacy Carisma issued an aggregate of 1,964,101 shares of Legacy Carisma common stock for an aggregate purchase price of approximately $30.6&#160;million, or the Private Placement, pursuant to an Amended and Restated Subscription Agreement, dated as of December&#160;29, 2022, or the Subscription Agreement, between Legacy Carisma and the selling stockholders. All of the shares of Legacy Carisma common stock held by the selling stockholders immediately prior to the effective time of the Merger, including shares of Legacy Carisma common stock issued in connection with the Private Placement, were exchanged into an aggregate of 3,730,608 shares of the Company&#8217;s common stock at the effective time of the Merger. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">For a detailed description of the transactions contemplated by the Subscription Agreement with the selling stockholders, see the section entitled &#8220;Selling Stockholders&#8221; in this prospectus. We filed the registration statement on Form S-3, of which this prospectus forms a part, to fulfill our contractual obligations under the Registration Rights Agreement with the selling stockholders, dated as of March&#160;7, 2023, or the Registration Rights Agreement, entered into concurrently with the consummation of the Private Placement to provide for the resale by the selling stockholders of the shares of common stock acquired pursuant to the Subscription Agreement. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock offered by selling stockholders </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">3,730,608 shares. </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We will not receive any proceeds from the sale of shares in this offering. </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk Factors </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You should read the &#8220;Risk Factors&#8221; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Nasdaq Global Market symbol </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;CARM&#8221;</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:512pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves significant risks. You should carefully consider the risks and uncertainties described in <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex99-3.htm">Exhibit&#160;99.3 to our Current Report on Form 8-K filed with the SEC on March&#160;8, 2023</a>, as updated by our subsequent filings, which are incorporated by reference into this prospectus, before deciding whether to purchase shares of our common stock. Each of the risk factors could adversely affect our business, financial condition, results of operations, or prospects, as well as adversely affect the value of an investment in our common stock, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tFOST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the information incorporated by reference in this prospectus contain certain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, the Exchange Act. All statements, other than statements of historical facts, contained in this prospectus and the information incorporated by reference herein, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;could&#8221;, &#8220;estimates&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;may&#8221;, &#8220;plans&#8221;, &#8220;potential&#8221;, &#8220;predicts&#8221;, &#8220;projects&#8221;, &#8220;should&#8221;, &#8220;will&#8221;, &#8220;would&#8221; and the negative version of these words and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The forward-looking statements in this prospectus and the documents incorporated by reference in the prospectus include, among other things, the statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing and conduct of our ongoing Phase&#160;1 clinical trial of CT-0508 and our planned clinical trial utilizing CT-0508 in combination with pembrolizumab; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing and conduct of our planned clinical trial of CT-0525 for solid tumors that overexpress HER2; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing and conduct of our planned clinical trial of CT-1119 for advanced mesothelin-positive solid tumors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing and conduct of our planned clinical trial of CT-0729 for prostate-specific membrane antigen positive castrate resistant prostate cancer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our plans to conduct discovery and pre-clinical testing of the development of in vivo CAR-M therapeutics for up to twelve oncology targets, as well as multiple other targets and indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to successfully enroll patients in and complete clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our plans to conduct discovery and pre-clinical testing of other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to realize the anticipated benefits of our research and development programs, strategic partnerships, research and licensing programs and academic and other collaborations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of applying for and receiving, and our ability to maintain, marketing approvals from applicable regulatory authorities for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain intellectual property protection and regulatory exclusivity for CT-0508 and any other product candidates we are developing or may develop in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">acceptance of CT-0508 and any other product candidates, if and when approved, by patients, the medical community and third-party payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents and short-term investments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential advantages of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates regarding the potential market opportunity for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our commercialization and manufacturing capabilities and strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of COVID-19 on our business and operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:324pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our competitive position; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of government laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to recognize the benefits of the Merger and the effect the completion of the Merger will have on our business relationships, operating results and business generally; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the receipt of any payments under the contingent value rights issued to our stockholders in connection with the closing of the Merger, the realization of value for Sesen Bio, Inc. legacy assets and the amount and timing of distributions to be made to our stockholders, if any; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">political and economic developments. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Forward-looking statements inherently involve known and unknown risks, uncertainties, and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions. You should carefully review the risk factors and cautionary statements described in the other documents we file from time to time with the SEC, specifically <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex99-3.htm">Exhibit&#160;99.3 to our Current Report on Form 8-K filed with the SEC on March&#160;8, 2023</a>, as updated by our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our other Current Reports on Form 8-K. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus and the documents incorporated by reference in this prospectus and the documents we have filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this prospectus are made as of the date of this prospectus, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:504pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders will pay any underwriting discounts, commissions, fees of underwriters, selling brokers or dealer managers and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees, printing fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SELLING STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;7, 2023, we completed the Merger. As of the effective time of the Merger, we changed our name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; and the business conducted by the Company became primarily the business conducted by Legacy Carisma, as described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Immediately prior to the effective time of the Merger, Legacy Carisma issued an aggregate of 1,964,101 shares of Legacy Carisma common stock to the selling stockholders in the Private Placement pursuant to the Subscription Agreement at a purchase price of $15.60 per share of Legacy Carisma common stock, for an aggregate purchase price of approximately $30.6&#160;million. The Private Placement was effected pursuant to an exemption from registration afforded by Section&#160;4(a)(2) of the Securities Act. At the effective time of the Merger, the shares purchased by the selling stockholders in the Private Placement were exchanged for 3,730,608 shares of our common stock in the aggregate, based on the exchange ratio set forth in the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the closing of the Private Placement, we entered into the Registration Rights Agreement, pursuant to which we agreed to, as promptly as reasonably practicable and in any event within 60&#160;days after the date of the Registration Rights Agreement, file a registration statement on Form S-3 with the SEC covering the resale of the shares of common stock sold in the Private Placement, or the Registrable Subscription Securities. We will use our reasonable best efforts to have the registration statement on Form&#160;S-3 declared effective by the SEC and maintain such effectiveness continuously for a period up to the earlier of (i)&#160;three&#160;years from the date of the Registration Rights Agreement and (ii)&#160;the date that all Registrable Subscription Securities covered by the registration statement on Form S-3 have been sold or can be sold without restriction pursuant to Rule&#160;144 promulgated by the SEC under the Securities Act, or SEC Rule&#160;144, or another similar exemption under the Securities Act and without the requirement to be in compliance with subsection (c)(1) of SEC Rule&#160;144 (or any successor thereto). The Registration Rights Agreement includes customary indemnification rights in connection with the registration statement. We filed the registration statement on Form S-3, of which this prospectus forms a part, to fulfill our contractual obligations under the Registration Rights Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing summary descriptions of the Subscription Agreement and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, which are filed as exhibits to the registration statement of which this prospectus is a part and are incorporated by reference herein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table below sets forth, to our knowledge, information concerning the beneficial ownership of shares of our common stock by the selling stockholders after closing of the Merger as of March&#160;7, 2023. The information in the table below with respect to the selling stockholders has been obtained from the selling stockholders. When we refer to the &#8220;selling stockholders&#8221; in this prospectus, we mean the selling stockholders listed in the table below as offering shares, as well as their respective transferees, pledgees or donees or other successors-in-interest. The selling stockholders may sell all, some or none of the shares of common stock subject to this prospectus. See &#8220;Plan of Distribution.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of common stock beneficially owned prior to the offering for each selling stockholder includes (i)&#160;all shares of common stock held by such selling stockholder as of March&#160;7, 2023, (ii)&#160;all shares as to which such selling stockholder has the right to acquire within 60&#160;days of March&#160;7, 2023 and (iii)&#160;all shares of common stock purchased by such selling stockholder in the Private Placement. The&#160;percentages of shares owned before and after the offering are based on 40,254,666 shares of common stock outstanding as of March&#160;7, 2023, which includes the outstanding shares of common stock offered by this prospectus. In computing the number of shares of common stock beneficially owned by a person and the&#160;percentage ownership of that person, we deemed outstanding shares of common stock issuable upon the exercise of options held by that selling stockholder that are exercisable within 60&#160;days of March&#160;7, 2023. We did not deem these shares outstanding, however, for the purpose of computing the&#160;percentage ownership of any other person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares. Unless otherwise indicated below, to our knowledge, each selling stockholder named in the table has sole voting and investment power with respect to the shares of common </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">stock beneficially owned by it, except to the extent authority is shared by spouses under applicable law. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for any selling stockholder named below. </font>
        </div>
        <table style="width:456pt;height:277pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:45.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:220.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Being</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offered </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to be</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After Offering</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Selling Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Healthcap VII L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,398,248</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.44<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">575,907</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,822,341</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.01<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AbbVie Biotechnology Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,749,855</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.83<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">462,674</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,287,181</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.68<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wellington Life Sciences V GmbH &amp; Co. KG</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,297,546</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.71<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">401,795</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,895,751</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.71<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Symbiosis II, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,215,877</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.50<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">389,620</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,826,257</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.54<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Trustees of the University of Pennsylvania</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,182,812</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.42<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">340,917</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,841,895</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.58<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">TPG Biotechnology Partners V L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,684,062</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.18<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">85,229</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,598,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.97<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MRL Ventures Fund&#160;LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,473,240</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.66<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">304,390</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,168,850</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.90<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Agent Capital Fund&#160;I LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,126,241</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.80<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">91,317</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,034,924</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.57<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aju Life Science 3.0 Venture Fund</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">718,332</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.78<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">109,580</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">608,752</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.51<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Livzon International Ventures I</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">718,332</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.78<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">109,580</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">608,752</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.51<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:220.52pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Pictet Thematic Private Equity, SICAV-RAIF&#8201;&#8211;&#8201;Pictet Thematic Private Equity&#8201;&#8211;&#8201;Health Fund&#160;I</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">669,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.66<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">669,660</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">b-to-v Partners S.&#224; r.l.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">654,001</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.62<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">109,580</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">544,421</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.35<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:220.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">4BIO Ventures II LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(14)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">445,628</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.11<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">80,359</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">365,269</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Less than 1% </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">We do not know when or in what amounts a selling stockholder may offer shares for sale. The selling stockholders might not sell any or might sell all of the shares offered by this prospectus. Because the selling stockholders may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the selling stockholders after completion of the offering. However, for purposes of this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;575,907 shares issued to Healthcap VII L.P. in the Private Placement and (ii)&#160;2,822,341 additional shares held by Healthcap VII L.P. HealthCap VII GP SA, a Swiss registered L.C.C., is the sole general partner of HealthCap VII, L.P. and has voting and investment control over the shares. HealthCap VII GP SA disclaims beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of their pecuniary interest therein. Fabrice Bernhard is the General Manager of HealthCap VII GP SA. Dag Richter, Daniel Schafer and Frans Wuite are each Directors of HealthCap VII GP SA. Each of Messrs. Bernhard, Richter, Schafer and Wuite may be deemed to share voting and investment power with respect to the shares held by HealthCap VII L.P. and disclaim beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of their pecuniary interest therein. Bj&#246;rn Odlander is a Managing Partner of VII Advisor AB, an affiliate of Healthcap VII L.P., and is a member of our board of directors. Dr.&#160;Odlander disclaims beneficial ownership of all shares held by HealthCap VII L.P. except to the extent of his pecuniary interest therein, if any. The business address of HealthCap VII L.P. is c/o&#160;HealthCap VII GP SA, Avenue Villamont 23, CH 1005 Lausanne Switzerland. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;462,674 shares issued to AbbVie Biotechnology Ltd. in the Private Placement and (ii)&#160;2,287,181 additional shares held by AbbVie Biotechnology Ltd. AbbVie Biotechnology Ltd. holds voting and investment control over the shares. The Board of Directors of AbbVie Biotechnology Ltd. consists of Lindsey Bristow, Jonathan C. Clipper, Stephen Muldoon and Arthur Price. Each of Ms.&#160;Bristow and each of Messrs. Clipper, Muldoon and Price may be deemed to share voting and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">investment power with respect to the shares held by AbbVie Biotechnology Ltd. and disclaim beneficial ownership of all shares held by AbbVie Biotechnology Ltd., except to the extent of their pecuniary interest therein, if any. The business address of AbbVie Biotechnology Ltd. is Thistle House, 4 Burnaby Street, Hamilton HM 11, Bermuda. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;401,795 shares issued to Wellington Life Sciences V GmbH &amp; Co. KG, or the Wellington Fund, in the Private Placement and (ii)&#160;1,895,751 additional shares held by the Wellington Fund. The Wellington Fund is represented by Wellington Life Sciences Venture Capital Consulting GmbH, or the Wellington General Partner. The Wellington General Partner holds voting and investment control over the shares. Dr.&#160;Regina Hodits and Dr.&#160;Rainer Strohmenger, in their functions as managing directors of the Wellington General Partner, have individual signatory power as well as voting and/or investment control over the shares. Dr.&#160;Regina Hodits is a member of our board of directors. Dr.&#160;Regina Hodits disclaims beneficial ownership of all shares held by the Wellington Fund except to the extent of her pecuniary interest therein, if any. The business address of the Wellington Fund and the Wellington General Partner is Tuerkenstrasse 5, 80333 Munich, Germany. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;389,620 shares issued to Symbiosis II, LLC in the Private Placement and (ii)&#160;1,826,257 additional shares held by Symbiosis II, LLC, which exercises voting and investment control of the shares. Chidozie Ugwumba is the Managing Partner of Symbiosis II, LLC and as such has sole voting and investment control over the shares. Mr.&#160;Ugwumba is also a member of our board of directors. The business address of Symbiosis II, LLC is 609 S.W. 8th Street, Suite 365, Bentonville, Arkansas 72712. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;340,917 shares issued to The Trustees of the University of Pennsylvania in the Private Placement and (ii)&#160;1,841,895 additional shares held by The Trustees of the University of Pennsylvania. The Board of Trustees of the University of Pennsylvania has voting and dispositive power over the shares. The Board of Trustees of the University of Pennsylvania is comprised of more than three individuals who have authority over the voting and disposition of the shares. A business address of The Trustees of the University of Pennsylvania is 2929 Walnut Street, Suite 300, Philadelphia, Pennsylvania 19104. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;85,229 shares issued to TPG Biotechnology Partners V, L.P., a Delaware limited partnership, in the Private Placement and (ii)&#160;1,598,833 additional shares held by TPG Biotechnology Partners V, L.P. The general partner of TPG Biotechnology Partners V, L.P. is TPG Biotechnology GenPar V, L.P., a Delaware limited partnership, whose general partner is TPG Biotech GenPar V Advisors, LLC, a Delaware limited liability company, whose sole member is TPG Operating Group I, L.P., a Delaware limited partnership, whose general partner is TPG Holdings I-A, LLC, a Delaware limited liability company, whose managing member is TPG GPCo, LLC, a Delaware limited liability company, whose managing member is TPG Inc., a Delaware corporation, whose shares of Class&#160;B common stock (which represent a majority of the combined voting power of the common stock) are held by TPG Group Holdings (SBS), L.P., a Delaware limited partnership, whose general partner is TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, whose managing member is TPG GP A, LLC, a Delaware limited liability company, which is owned by entities owned by David Bonderman, James G. Coulter and Jon Winkelried. Messrs. Bonderman, Coulter and Winkelried may therefore be deemed to share voting and investment power with respect to, and thus beneficially own the securities directly held by TPG Biotechnology Partners V, L.P. Messrs. Bonderman, Coulter and Winkelried disclaim beneficial ownership of the securities directly held by TPG Biotechnology Partners&#160;V, L.P. except to the extent of their pecuniary interest therein. The address of each of TPG GP A,&#160;LLC and Messrs. Bonderman, Coulter and Winkelried is 301 Commerce Street, Suite 3300, Fort Worth, Texas 76102. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;304,390 shares issued to MRL Ventures Fund&#160;LLC in the Private Placement and (ii)&#160;1,168,850 additional shares held by MRL Ventures Fund&#160;LLC. MRL Ventures Fund, LLC holds investment and voting control over the shares. Peter Dudek, Sunil Patel, Dean Li, Caroline Litchfield, Eliav Barr and George Adonna are members of the investment committee of MRL Ventures Fund, LLC. Each of Messrs. Dudek, Patel, Li, Miletich, Litchfield, Barr and Adonna may be deemed to share voting and investment power with respect to the shares held by MRL Ventures Fund, LLC and disclaim beneficial ownership of all shares held by MRL Ventures Fund, LLC, except to the extent of their pecuniary interest therein. The business address of MRL Ventures Fund, LLC is One Merck Drive, Whitehouse Station, New Jersey 08889. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;91,317 shares issued to Agent Capital Fund&#160;I LP in the Private Placement and (ii)&#160;1,034,924 additional shares held by Agent Capital Fund&#160;I LP. Agent Capital Fund&#160;I LP is a Delaware limited partnership whose general partner is Agent Capital Fund&#160;I GP, LLC, or ACGPI, a Delaware limited liability company. Geeta Vemuri is the managing member of ACGPI and exercises voting and investment power with respect to the shares owned by Agent Capital Fund&#160;I LP. ACGPI and Ms.&#160;Vemuri disclaim beneficial ownership of all shares held by Agent Capital Fund&#160;I LP, except to the extent of their respective pecuniary interests therein. The address of each of Agent Capital Fund&#160;I LP, ACGPI and Ms.&#160;Vemuri is 1400 Main Street, Floor 1, Waltham, MA 02451. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:3.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i) 109,580 shares issued to Aju Life Science 3.0 Venture Fund in the Private Placement and (ii)&#160;608,752 additional shares held by Aju Life Science 3.0 Venture Fund. Aju IB Investment is the general partner of Aju Life Science 3.0 Venture Fund, and Solasta Ventures is a subsidiary of Aju IB Investment. Derek Yoon in his capacity as President and Chief Executive Officer of Solasta Ventures and Ji-won Kim in his capacity as Chief Executive Officer of Aju IB Investment have sole voting and investment control over the shares. Mr. Yoon and Mr. Kim. disclaim beneficial ownership of all shares held by Aju Life Science 3.0 Venture Fund, except to the extent of their pecuniary interest therein, if any. The address of Aju Life Science 3.0 Venture Fund is 201 Teheran-ro, Floor, Gangnam-gu, Seoul, Korea 06141. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:3.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;109,580 shares issued to Livzon International Ventures I in the Private Placement and (ii)&#160;608,752 additional shares held by Livzon International Ventures I. Livzon Pharmaceutical Group Inc. (SHE: 000513, HK: 01513), whose outstanding shares are publicly-held and listed on the Shenzhen Stock Exchange and the HongKong Stock Exchange, wholly owns Livzon International Ventures I. The address of Livzon International Ventures I is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of shares issued to Pictet Thematic Private Equity, SICAV-RAIF&#8201;&#8212;&#8201;Pictet Thematic Private Equity&#8201;&#8212;&#8201;Health Fund&#160;I, or Pictet, in the Private Placement. Jens Hoellermann, Francesco Ilardi, Aur&#233;lien Favier and Yves Kuhn may be deemed to have voting and dispositive power over the shares held by Pictet . The address for each of Messrs. Jens Hoellermann, Francesco Ilardi, Aur&#233;lien Favier and Yves Kuhn is 15 Avenue J.F. Kennedy, L-1855 Luxembourg. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:3.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;109,580 shares issued to b-to-v Partners S.&#224; r.l. in the Private Placement and (ii)&#160;544,421 additional shares held by b-to-v Partners S.&#224; r.l. Dr.&#160;Christian Sch&#252;tz and Florian Schweitzer, each in their capacity as Managing Directors of b-to-v Partners S.&#224; r.l., have sole voting and investment control over the shares. Dr.&#160;Sch&#252;tz and Mr.&#160;Schweitzer disclaim beneficial ownership of all shares held by b-to-v Partners S.&#224; r.l., except to the extent of their pecuniary interest therein, if any. The address of b-to-v Partners S.&#224; r.l. is 1c, rue Gabriel Lippmann, 5365 Munsbach, Luxembourg. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:3.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;80,359 shares issued to 4BIO Ventures II LP in the Private Placement and (ii)&#160;365,269 additional shares held by 4BIO Ventures II LP. 4BIO Ventures II GP Ltd, the general partner of 4BIO Ventures II LP, has voting and investment control with respect to the shares. Andrey Kozlov, Dmitry Kuzmin and Kieran Mudryy in their functions as directors of 4BIO Ventures II GP Ltd, have individual signatory power as well as voting and/or investment control over the shares. The address of 4BIO Ventures&#160;II LP is 78 Pall Mall, London SW1Y 5ES United Kingdom. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Relationships with Selling Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Board of Directors</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, who is a member of our board of directors, is Managing Partner of HealthCap VII Advisor AB, an affiliate of Healthcap VII L.P., which is a selling stockholder. Chidozie Ugwumba, who is a member of our board of directors, is the Managing Partner of Symbiosis II, LLC, which is a selling stockholder. Dr.&#160;Regina Hodits, who is a member of our board of directors, is a director of Wellington General Partner, an affiliate of the Wellington Fund, which is a selling stockholder. Margarita Chavez, who was a former director of Legacy Carisma until March&#160;7, 2023, is employed as a Managing Director of AbbVie Ventures, an affiliate of AbbVie Biotechnology Ltd., which is a selling stockholder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Series&#160;A Convertible Preferred Stock Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2018, November&#160;2018 and March&#160;2020, Legacy Carisma and CARISMA Therapeutics S.&#224; r.l., a soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e organized under the laws of Luxembourg and a subsidiary of Legacy </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma, or Carisma Europe, as applicable, issued and sold an aggregate of 5,201,017 shares of the Legacy Carisma Series&#160;A preferred stock, $0.0001 par value per share and an aggregate of 937,501 Class&#160;B Shares, with a nominal value of one tenth of one eurocent (EUR 0.001), of Carisma Europe, or the Class&#160;B exchangeable shares, of which (i)&#160;4,701,925 shares of Series&#160;A preferred stock and all of the Class&#160;B exchangeable shares were sold at a price per share of $10.40 in cash, for an aggregate purchase price of $58,650,030.40 and (ii)&#160;499,092 shares of Legacy Carisma Series&#160;A preferred stock were sold at a price per share of $8.06 against payment by cancellation or conversion of indebtedness of Legacy Carisma to the applicable purchaser, including interest. Legacy Carisma also issued one share of Special Voting Preferred Stock of Legacy Carisma, $0.0001 par value per share, to the holder of the Class&#160;B exchangeable shares, which share was automatically cancelled when the Class&#160;B exchangeable shares were exchanged for capital stock of Legacy Carisma immediately prior to the effective time of the Merger. All of the shares of Legacy Carisma preferred stock held by the selling stockholders were exchanged for shares of the Company&#8217;s common stock at the effective time of the Merger. The following selling stockholders participated in the Series&#160;A convertible preferred stock financing: AbbVie Biotechnology Ltd., Agent Capital Fund&#160;I LP, b-to-v Partners S.&#224; r.l., Healthcap VII L.P., MRL Ventures Fund&#160;LLC, The Trustees of the University of Pennsylvania, TPG Biotechnology Partners V L.P. and Wellington Life Sciences V GmbH &amp; Co. KG. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Series&#160;B Convertible Preferred Stock Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020 and February&#160;2021, Legacy Carisma and Carisma Europe, as applicable, issued and sold an aggregate of 3,499,866 shares of the Legacy Carisma Series&#160;B preferred stock, $0.0001 par value per share and an aggregate of 297,764 Class&#160;B-1 Shares, with a nominal value of one tenth of one eurocent (EUR 0.001), of Carisma Europe, or the Class&#160;B-1 exchangeable shares, all of which were sold at a price per share of $15.60 in cash, for an aggregate purchase price of $59,243,028.00. Legacy Carisma also issued one share of Legacy Carisma Series&#160;B special voting preferred stock, $0.0001 par value per share, to the holder of the Class&#160;B-1 exchangeable shares, which share was automatically cancelled when the Class&#160;B-1 exchangeable shares were exchanged for capital stock of Legacy Carisma immediately prior to the effective time of the Merger. All of the shares of Legacy Carisma preferred stock held by the selling stockholders were exchanged for shares of the Company&#8217;s common stock at the effective time of the Merger. The following selling stockholders participated in the Series&#160;B convertible preferred stock financing: 4BIO Ventures II LP, AbbVie Biotechnology Ltd., Agent Capital Fund&#160;I LP, Aju Life Science 3.0 Venture Fund, b-to-v Partners S.&#224; r.l., Healthcap VII L.P., Livzon International Ventures I, MRL Ventures Fund&#160;LLC, Symbiosis II, LLC, The Trustees of the University of Pennsylvania, TPG Biotechnology Partners V L.P. and Wellington Life Sciences V GmbH &amp; Co. KG. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investor Rights Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, Legacy Carisma and Carisma Europe entered into an amended and restated investor rights agreement, or the Investor Rights Agreement, with certain holders of Legacy Carisma common stock, the Series&#160;A preferred stock, Series&#160;B preferred stock, Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares, including certain holders of 5% of Legacy Carisma&#8217;s capital stock, and including certain affiliates of Legacy Carisma&#8217;s directors and their affiliates. The Investor Rights Agreement provided such holders with certain registration rights, including the right to demand that Legacy Carisma file a registration statement or request that their shares be covered by a registration statement that Legacy Carisma is otherwise filing. The Investor Rights Agreement also provided certain major investors with certain information and observer rights. The Investor Rights Agreement was terminated in connection with the closing of the Merger. The following selling stockholders were party to the Investor Rights Agreement: 4BIO Ventures II LP, AbbVie Biotechnology Ltd., Agent Capital Fund&#160;I LP, Aju Life Science 3.0 Venture Fund, b-to-v Partners S.&#224; r.l., Healthcap VII L.P., Livzon International Ventures I, MRL Ventures Fund&#160;LLC, Symbiosis II, LLC, The Trustees of the University of Pennsylvania, TPG Biotechnology Partners V L.P. and Wellington Life Sciences V GmbH &amp; Co. KG. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Voting Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, Legacy Carisma and Carisma Europe entered into an amended and restated voting agreement, or the Voting Agreement, with certain holders of Legacy Carisma common stock, Series&#160;A preferred stock, Series&#160;B preferred stock, Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">including certain holders of 5% of Legacy Carisma&#8217;s capital stock, and including certain of Legacy Carisma&#8217;s directors and their affiliates. Pursuant to the Voting Agreement, such holders party thereto agreed to vote their shares in favor of the election of certain directors and specified transactions approved by the requisite majority of the shares of voting capital stock held by such holders. The Voting Agreement was terminated in connection with the closing of the Merger. The following selling stockholders were party to the Voting Agreement: 4BIO Ventures II LP, AbbVie Biotechnology Ltd., Agent Capital Fund&#160;I LP, Aju Life Science&#160;3.0 Venture Fund, b-to-v Partners S.&#224; r.l., Healthcap VII L.P., Livzon International Ventures I, MRL Ventures Fund&#160;LLC, Symbiosis II, LLC, The Trustees of the University of Pennsylvania, TPG Biotechnology Partners V L.P. and Wellington Life Sciences V GmbH &amp; Co. KG. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Right of First Refusal and Co-Sale Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, Legacy Carisma entered into an amended and restated right of first refusal and co-sale agreement, or the ROFR Agreement, with certain holders of Legacy Carisma common stock, the Series&#160;A preferred stock, Series&#160;B preferred stock, Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares, including certain holders of 5% of its capital stock, and including certain of Legacy Carisma&#8217;s directors and their affiliates. Pursuant to the ROFR Agreement, Legacy Carisma had a right of first refusal in respect of certain sales of securities by certain holders of its capital stock. To the extent Legacy Carisma did not exercise such right in full, certain holders of its capital stock were granted certain rights of first refusal and co-sale in respect of such sales. The ROFR Agreement was terminated in connection with the closing of the Merger. The following selling stockholders were party to the ROFR Agreement: 4BIO Ventures II LP, AbbVie Biotechnology Ltd., Agent Capital Fund&#160;I LP, Aju Life Science 3.0 Venture Fund, b-to-v Partners S.&#224; r.l., Healthcap VII L.P., Livzon International Ventures I, MRL Ventures Fund&#160;LLC, Symbiosis II, LLC, The Trustees of the University of Pennsylvania, TPG Biotechnology Partners V L.P. and Wellington Life Sciences V GmbH &amp; Co. KG. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Share Exchange and Voting Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, Legacy Carisma and Carisma Europe entered into an amended and restated share exchange and voting agreement, or the Share Exchange Agreement, with certain holders of the Series&#160;A preferred stock, Series&#160;B preferred stock, Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares, including certain holders of 5% of its capital stock, and including certain of Legacy Carisma&#8217;s directors and their affiliates. The Share Exchange Agreement provided for the exchange of the Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares for shares of Series&#160;A preferred stock and Series&#160;B preferred stock, respectively, either voluntarily or automatically, upon certain circumstances as set forth therein. In connection with the closing of the Merger, the Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares were exchanged into Legacy Carisma preferred stock, and the Share Exchange Agreement terminated. The following selling stockholders were party to the Share Exchange Agreement: 4BIO Ventures II LP, AbbVie Biotechnology Ltd., Agent Capital Fund&#160;I LP, Aju Life Science 3.0 Venture Fund, b-to-v Partners S.&#224; r.l., Healthcap VII L.P., Livzon International Ventures I, MRL Ventures Fund&#160;LLC, Symbiosis II, LLC, The Trustees of the University of Pennsylvania, TPG Biotechnology Partners V L.P. and Wellington Life Sciences V GmbH &amp; Co. KG. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">University of Pennsylvania License Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2017, Legacy Carisma entered into a license agreement with the Trustees of the University of Pennsylvania, or Penn, which was amended in February&#160;2018, January&#160;2019, March&#160;2020 and June&#160;2021, or the Penn License Agreement. Pursuant to the Penn License Agreement, Legacy Carisma is responsible for paying Penn an annual license maintenance fee in the low tens of thousands of dollars, payable until Legacy Carisma&#8217;s first payment of a royalty. Legacy Carisma is required to pay Penn up to $10.9&#160;million per product in development and regulatory milestone payments, up to $30.0&#160;million per product in commercial milestone payments, and up to an additional $1.7&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. As of April&#160;17, 2023, Penn is a holder of 5% or more of our voting securities and a selling stockholder.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our Restated Certificate of Incorporation, or certificate of incorporation, our Amended and Restated By-laws, or by-laws, and applicable provisions of Delaware corporate law. You should read our certificate of incorporation and by-laws, which are filed as exhibits to the registration statement of which this prospectus forms a part, for the provisions that are important to you. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our authorized capital stock consists of 100,000,000 shares of common stock and 5,000,000 shares of preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Annual Meeting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Annual meetings of our stockholders are held on the date designated in accordance with our by-laws. Written notice must be mailed to each stockholder entitled to vote not less than ten nor more than 60&#160;days before the date of the meeting. The presence in person or by proxy of the holders of record of a majority of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders may be called at any time only by the board of directors, stating the purpose of such meeting. Except as may be otherwise provided by applicable law, our certificate of incorporation or our by-laws, all elections shall be decided by a plurality, and all other questions shall be decided by a majority, of the votes cast by stockholders entitled to vote thereon at a duly held meeting of stockholders at which a quorum is present. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Voting Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote for each share held of record on all matters to be voted upon by stockholders, including the election of directors. Our certificate of incorporation and by-laws do not provide for cumulative voting rights.Except as otherwise provided by law, our certificate of incorporation and by-laws, in all matters other than the election of directors, the affirmative vote of the majority of the shares present in person or represented by proxy at a meeting at which a quorum is present and entitled to vote on the subject matter shall be the act of the stockholders. Directors shall be elected by a plurality of the shares present in person or represented by proxy at a meeting at which a quorum is present and entitled to vote on the election of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividends</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the rights, powers and preferences of any outstanding preferred stock, and except as provided by law or in our certificate of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and as declared by the board of directors. The payment of dividends is contingent upon our revenue and earnings, capital requirements, and general financial condition, as well as contractual restrictions and other considerations deemed to be relevant by our board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Liquidation, Dissolution and Winding Up</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the rights, powers and preferences of any outstanding preferred stock, in the event of our liquidation, dissolution or winding up, our net assets will be distributed pro&#160;rata to the holders of our common stock. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Rights</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of the common stock have no right to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">convert the stock into any other security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">have the stock redeemed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchase additional stock; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">maintain their proportionate ownership interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of shares of the common stock are not required to make additional capital contributions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Transfer Agent and Registrar</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Computershare Trust Company, N.A. is transfer agent and registrar for the common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors is authorized to issue up to 5,000,000 shares of preferred stock in one or more series, with such rights, preferences and privileges as shall be determined by our board of directors. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of shares of any series of our preferred stock that we may classify and issue in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Provisions of Our Certificate of Incorporation and By-laws and Delaware Law That May Have Anti-Takeover Effects</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain provisions of our certificate of incorporation and by-laws may have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, control of us. Such provisions could limit the price that certain investors might be willing to pay in the future for shares of our common stock and may limit the ability of stockholders to remove current management or directors or approve transactions that stockholders may deem to be in their best interest and, therefore, could adversely affect the price of our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">No Cumulative Voting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law, or the DGCL, provides that stockholders are not entitled to the right to accumulate votes in the election of directors unless our certificate of incorporation provides otherwise. Our certificate of incorporation does not provide for cumulative voting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Board of Directors</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our certificate of incorporation and by-laws provide for a board of directors divided as nearly equally as possible into three classes. Each class is elected to a term expiring at the annual meeting of stockholders held in the third year following the year of such election. The number of directors comprising our board of directors is fixed from time to time by the board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Removal of Directors by Stockholders</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Delaware law provides that members of our board of directors may only be removed for cause by a vote of the holders of at least seventy-five&#160;percent (75%) of the outstanding shares entitled to vote on the election of the directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Board Vacancies Filled Only by Majority of Directors Then in Office</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Vacancies and newly created seats on our board may be filled only by a vote of a majority of our board of directors. Further, only our board of directors may determine the number of directors on our board. The inability of stockholders to determine the number of directors or to fill vacancies or newly created seats on the board makes it more difficult to change the composition of our board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stockholder Nomination of Directors</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our by-laws provide that a stockholder must notify us in writing of any stockholder nomination of a director not earlier than, the 120</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day and not later than on the 90</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, that if the date of the annual meeting is advanced or delayed by more than 30&#160;days from such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the 120</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day prior to the date of such annual meeting and not later than on the later of (x)&#160;the 90</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day prior to the date of such meeting and (y)&#160;the 10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day following the day on which public announcement of the date of such annual meeting is first made by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">No Action By Written Consent</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that our stockholders may not act by written consent and may only act at duly called meetings of stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Undesignated Preferred Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As discussed above, our board of directors has the ability to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Super-Majority Voting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Delaware law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater&#160;percentage. Our by-laws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:40pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These provisions of Delaware law, our certificate of incorporation and by-laws may have the effect of deterring hostile takeovers or delaying changes in our control or in our management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and in the policies they implement, and to discourage certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware Business Combination Statute.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We are subject to Section&#160;203 of the DGCL, or Section&#160;203, which prohibits a Delaware corporation from engaging in business combinations with an interested stockholder. An interested stockholder is generally defined as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation or any entity or person affiliated with or controlling or controlled by such entity or person, or interested stockholder. Section&#160;203 provides that an interested stockholder may not engage in business combinations with the corporation for a period of three&#160;years after the date that such stockholder became an interested stockholder, with the following exceptions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i)&#160;by persons who are directors and also officers and (ii)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, Section&#160;203 defines business combinations to include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any merger or consolidation involving the corporation and the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any sale, lease, transfer, pledge or other disposition of 10% or more of the assets of the corporation to or with the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an exchange distribution in accordance with the rules of the applicable exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">privately negotiated transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">short sales; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">broker-dealers may agree with a selling stockholder to sell a specified number of such shares at a stipulated price per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a combination of any such methods of sale; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other method permitted by applicable law. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule&#160;424(b)(3) or other applicable provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:172pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule&#160;144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#8220;underwriters&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &#8220;underwriters&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have advised the selling stockholders that the anti-manipulation rules of Regulation&#160;M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed with the selling stockholders to use reasonable best efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to maintain such effectiveness continuously for a period up to the earlier of (i)&#160;three&#160;years from the date of the Registration Rights Agreement and (ii)&#160;the date that all Registrable Subscription Securities covered by the registration statement on Form S-3 have been sold or can be sold without restriction pursuant to SEC Rule&#160;144, or another similar exemption under the Securities Act and without the requirement to be in compliance with subsection&#160;(c)(1) of SEC Rule&#160;144 (or any successor thereto). </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:412pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the shares of our common stock offered by this prospectus has been passed upon for us by Wilmer Cutler Pickering Hale and Dorr LLP. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited the consolidated financial statements of Carisma Therapeutics Inc. (formerly Sesen Bio, Inc.) included in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000090/sesn-20221231.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022</a>, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Such financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Carisma Therapeutics Inc. as of December&#160;31, 2022 and 2021, and for the&#160;years then ended, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a><a name="tIBR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at www.carismatx.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings and the exhibits attached thereto. You should review the complete document to evaluate these statements. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-36296) and any future filings we make with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000090/sesn-20221231.htm">Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022</a>, as filed with the SEC on February&#160;28, 2023, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2023 Annual Meeting of Stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Current Reports on Form 8-K as filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000010/sesn-20230125.htm">January&#160;30, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000014/sesn-20230131.htm">January&#160;31, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000020/sesn-20230131.htm">February&#160;1, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000110465923009939/tm235275d1_8k.htm">February&#160;2, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000031/sesn-20230207.htm">February&#160;7, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000110465923020879/tm236507d1_8k.htm">February&#160;14, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000068/sesn-20230224.htm">February&#160;27, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000096/sesn-20230302.htm">March&#160;2, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000099/sesn-20230306.htm">March&#160;6, 2023</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000110465923029687/tm238578d1_8k.htm">March&#160;8, 2023</a>, and <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000110465923041238/tm239286d1_8ka.htm">April&#160;4, 2023</a>; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The description of our common stock contained in our registration statement on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514032959/d668910d8a12b.htm">Form 8-A, as filed with the SEC under the Exchange Act on February&#160;3, 2014</a>, as the description therein has been updated and superseded by the description of our capital stock contained on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit41-fy2021form10xk.htm">Exhibit&#160;4.1 to our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022</a> and our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000110465923029687/tm238578d1_8k.htm">Current Report on Form 8-K as filed with the SEC on March&#160;8, 2023</a>, including any amendment or report filed for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma Therapeutics Inc. </font>
          <br >
          <font style="letter-spacing:0.2pt;">3675 Market Street, Suite 200 </font>
          <br >
          <font style="letter-spacing:0.2pt;">Philadelphia, PA 19104</font>
          <br >
          <font style="letter-spacing:0.2pt;">Attn: Investor Relations </font>
          <br >
          <font style="letter-spacing:0.2pt;">(267) 491-6422</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:140.18pt; text-align:center; width:456pt;">
          <img src="lg_carismatherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_carismatherapeutics-4c.jpg]" height="79" width="289" >
        </div>
        <div style="margin-top:13.91pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">3,730,608 SHARES</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:9.63pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">COMMON STOCK</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:33.603pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 33.6033333333334pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:13.42pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font>
        </div>
        <div style="margin-top:15.62pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 15.6199999999999pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:220.47pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2023</font>
        </div>
        <div style="margin-top:140.07pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 140.07pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PART II</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;14.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the various expenses to be incurred in connection with the sale and distribution of the securities being registered hereby, all of which will be borne by Carisma Therapeutics Inc. (except any underwriting discounts, commissions, fees of underwriters, selling brokers or dealer managers and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the shares). All amounts shown are estimates except the SEC registration fee. </font>
        </div>
        <table style="width:416pt;height:85.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:371.29pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">78,152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;15.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;102 of the DGCL permits a corporation to eliminate the personal liability of its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The registrant&#8217;s certificate of incorporation provides that no director shall be personally liable to the registrant or the registrant&#8217;s stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The registrant&#8217;s certificate of incorporation provides that the registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the registrant), by reason of the fact that he or she is or was, or has agreed to become, the registrant&#8217;s director or officer, or is or was serving, or has agreed to serve, at the registrant&#8217;s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom if such Indemnitee acted in good faith and in a manner </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">he or she reasonably believed to be in, or not opposed to, the registrant&#8217;s best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The registrant&#8217;s certificate of incorporation also provides that the registrant will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the registrant to procure a judgment in the registrant&#8217;s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, the registrant&#8217;s director or officer, or is or was serving, or has agreed to serve, at the registrant&#8217;s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the registrant&#8217;s best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the registrant against all expenses (including attorneys&#8217; fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the registrant has entered into indemnification agreements with all of the registrant&#8217;s executive officers and directors. In general, these agreements provide that the registrant will indemnify the executive officer or director to the fullest extent permitted by law for claims arising in his or her capacity as an executive officer or director of the registrant or in connection with his or her service at the registrant&#8217;s request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that an executive officer or director makes a claim for indemnification and establish certain presumptions that are favorable to the executive officer or director. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The registrant maintains a general liability insurance policy that covers certain liabilities of the registrant&#8217;s directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Exhibit&#160;Index</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:200.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Exhibit&#160;No. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:405.09pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:9.75pt; white-space:nowrap;text-align:right;">2.1</td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit21-projectseahawkxm.htm">Agreement and Plan of Merger and Reorganization, dated as of September&#160;20, 2022, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc., and CARISMA Therapeutics Inc. (incorporated by reference to Exhibit&#160;2.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on September&#160;21, 2022)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:9.75pt; white-space:nowrap;text-align:right;">2.2</td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:405.09pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500322000182/projectseahawk-firstamen.htm">First Amendment to Agreement and Plan of Merger and Reorganization, dated as of </a>
              <br >
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500322000182/projectseahawk-firstamen.htm">December&#160;29, 2022, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc., and CARISMA </a>
              <br >
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500322000182/projectseahawk-firstamen.htm">Therapeutics, Inc. (incorporated by reference to Exhibit&#160;2.1 to the registrant&#8217;s Current Report </a>
              <br >
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500322000182/projectseahawk-firstamen.htm">on Form 8-K (File No. 001-36296) filed on December&#160;29, 2022)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:9.75pt; white-space:nowrap;text-align:right;">2.3</td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923020879/tm236507d1_ex2-1.htm">Second Amendment to Agreement and Plan of Merger and Reorganization, dated as of February&#160;13, 2023, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc., and CARISMA Therapeutics, Inc. (incorporated by reference to Exhibit&#160;2.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on February&#160;14, 2023)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:9.75pt; white-space:nowrap;text-align:right;">4.1</td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex3-1.htm">Restated Certificate of Incorporation of Carisma Therapeutics Inc., dated March&#160;7, 2023 (incorporated by reference to Exhibit&#160;3.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March&#160;8, 2023)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:227.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:justify;">
                <font style="letter-spacing:-0.16pt;">Exhibit&#160;No. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:405.09pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">4.2</td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex3-2.htm">Amended and Restated By-Laws of Carisma Therapeutics Inc., dated March&#160;7, 2023 (incorporated by reference to Exhibit&#160;3.2 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March&#160;8, 2023)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">4.3</td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923002376/tm2227887d12_ex10-35.htm">Amended and Restated Subscription Agreement, dated as of December&#160;29, 2022, by and </a>
              <br >
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923002376/tm2227887d12_ex10-35.htm">between Carisma and each of the purchasers listed on the signature pages thereto, severally and </a>
              <br >
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923002376/tm2227887d12_ex10-35.htm">not jointly (incorporated by reference to Exhibit&#160;10.35 to the registrant&#8217;s registration statement </a>
              <br >
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923002376/tm2227887d12_ex10-35.htm">on Form S-4/A (No. 333-267891) filed on January&#160;10, 2023)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">4.4</td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-4.htm">Registration Rights Agreement, dated March&#160;7, 2023 (incorporated by reference to Exhibit&#160;10.4 </a>
              <br >
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-4.htm">to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on September&#160;21, </a>
              <br >
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-4.htm">2022)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">5.1<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2312861d2_ex5-1.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">23.1<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2312861d2_ex23-1.htm">Consent of KPMG LLP, independent registered public accounting firm</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">23.2<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2312861d2_ex23-2.htm">Consent of Ernst &amp; Young LLP, independent registered public accounting firm</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">23.3<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2312861d2_ex5-1.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit&#160;5.1)</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">24.1<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a href="#tSIG">Powers of Attorney (included in the signature pages to the registration statement)</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:right;">107<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:21.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2312861d2_exfiling-fees.htm">Filing Fee Table</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Filed herewith </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:29pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:49pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act, that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of this registration statement. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.89pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:8.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:84pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability under the Securities Act to any purchaser: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii)&#160;or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(c)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Philadelphia, Commonwealth of Pennsylvania, on April&#160;17, 2023. </font>
        </div>
        <table style="width:510pt;height:61.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:276pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;" colspan="7">
              <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:276pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:14.5pt 0pt 1.5pt 0pt; width:12pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:14.5pt 0pt 1.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:0.2pt;">/s/ Steven Kelly</font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:276pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:0.2pt;">Steven Kelly</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:276pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SIGNATURES AND POWER OF ATTORNEY </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We, the undersigned officers and directors of Carisma Therapeutics Inc. hereby severally constitute and appoint Steven Kelly, Richard Morris and Thomas Wilton, and each of them singly, our true and lawful attorneys-in-fact with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration statement on Form S-3 filed herewith and any and all amendments (including post-effective amendments) to said registration statement, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in our name and on our behalf in our capacities as officers and directors to enable Carisma Therapeutics Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue hereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </font>
        </div>
        <table style="width:456pt;height:304.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:180.01pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:11.917pt 0pt 0.5pt 0pt; width:180.01pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Steven Kelly</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 180.01pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Steven Kelly </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:11.917pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">President, Chief Executive Officer, Director</font>
              <br >
              <font style="letter-spacing:0.2pt;">(Principal Executive Officer) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:11.917pt 0pt 0.5pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">April&#160;17, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.01pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Richard Morris</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 180.01pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Richard Morris </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
              <br >
              <font style="letter-spacing:0.2pt;">(Principal Financial and Accounting Officer) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">April&#160;17, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.01pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Sanford Zweifach</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 180.01pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Sanford Zweifach </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">Director and Chair of the Board </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">April&#160;17, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.01pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Regina Hodits, Ph.D.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 180.01pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">April&#160;17, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.01pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Briggs Morrison, M.D.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 180.01pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">April&#160;17, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.01pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Bj&#246;rn Odlander, M.D.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 180.01pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">April&#160;17, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.01pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Michael Torok</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 180.01pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Michael Torok </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">April&#160;17, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.01pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Chidozie Ugwumba</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 180.01pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.167pt 0pt 0.5pt 0pt; width:59.99pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">April&#160;17, 2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2312861d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right"><FONT><B>Exhibit&nbsp;5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2312861d2_ex5-img002.gif" ALT="" STYLE="height: 16px; width: 123px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT>+1 617
526 6000 (t)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">+1 617 526 5000 (f)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT>wilmerhale.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;17, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3675 Market St., Suite&nbsp;200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philadelphia, Pennsylvania 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Re:</TD><TD><U>Registration Statement on Form&nbsp;S-3</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
opinion is furnished to you in connection with a Registration Statement on Form&nbsp;S-3 (the &ldquo;Registration Statement&rdquo;) filed
with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), for the registration of an aggregate of </FONT>3,730,608 shares of Common Stock, $0.001 par value per share (the &ldquo;Shares&rdquo;),
of Carisma Therapeutics Inc. (formerly Sesen Bio,&nbsp;Inc.), a Delaware corporation (the &ldquo;Company&rdquo;). All of the Shares are
being registered on behalf of certain stockholders of the Company (the &ldquo;Selling Stockholders&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are acting as counsel for the Company in connection
with the registration for resale of the Shares. We have examined signed copies of the Registration Statement filed with the Commission.
We have also examined and relied upon minutes of meetings of the stockholders and the Board of Directors of the Company as provided to
us by the Company, stock record books of the Company as provided to us by the Company, the Restated Certificate of Incorporation and Amended
and Restated By-Laws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for
purposes of rendering the opinions hereinafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In our examination of the foregoing documents,
we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original
documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence
of all signatories to such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our opinion below, insofar as it relates to the
Selling Stockholders&rsquo; shares being fully paid, is based solely on a certificate of the Chief Financial Officer of the Company confirming
the Company&rsquo;s receipt of the consideration called for by the applicable resolutions authorizing the issuance of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We assume that the appropriate action will be taken,
prior to the offer and sale of the Shares, to register and qualify the Shares for sale under all applicable state securities or &ldquo;blue
sky&rdquo; laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We express no opinion herein as to the laws of
any state or jurisdiction other than the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2312861d2_ex5-img001.jpg" ALT="" STYLE="height: 26px; width: 622px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT>April&nbsp;17, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: lightgrey"><IMG SRC="tm2312861d2_ex5-img002.gif" ALT="" STYLE="height: 16px; width: 123px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">Based upon and subject to the foregoing, we are
of the opinion that the Shares have been duly authorized and are validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is understood that this opinion is to be used
only in connection with the offer and sale of the Shares while the Registration Statement is in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please note that we are opining only as to the
matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing
statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources
of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to the filing of this opinion
with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5)&nbsp;of Regulation
S-K under the Securities Act and to the use of our name therein and in the related prospectus under the caption &ldquo;Legal Matters.&rdquo;
In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of
the Securities Act or the rules&nbsp;and regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Wilmer Cutler Pickering Hale and Dorr LLP</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">WILMER CUTLER PICKERING HALE AND DORR
    LLP</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2312861d2_ex5-img001.jpg" ALT="" STYLE="height: 26px; width: 622px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm2312861d2_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the use of our report dated April&nbsp;4,&nbsp;2023,
with respect to the consolidated financial statements of Carisma Therapeutics Inc., incorporated herein by reference and to the reference
to our firm under the heading &quot;Experts&quot; in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">/s/ KPMG LLP &nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Philadelphia, Pennsylvania</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">April&nbsp;14,&nbsp;2023</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>tm2312861d2_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #333333"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #333333"><B>Exhibit&nbsp;23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #333333"><B>Consent of Independent Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333">We consent to the reference to our firm under the caption
 &ldquo;Experts&rdquo; in the Registration Statement (Form&nbsp;S-3) and related Prospectus of Carisma Therapeutics Inc. (f/k/a Sesen Bio,&nbsp;Inc.)
for the registration of 3,730,608 shares of its common stock and to the incorporation by reference therein of our report dated February&nbsp;28,
2023, with respect to the consolidated financial statements of Sesen Bio,&nbsp;Inc., included in its Annual Report (Form&nbsp;10-K) for
the year ended December&nbsp;31, 2022, filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Ernst&nbsp;&amp; Young LLP</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Boston, Massachusetts</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">April&nbsp;17, 2023</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>tm2312861d2_exfiling-fees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form&nbsp;Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Carisma Therapeutics
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 1: Newly Registered and Carry Forward
Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U></U></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; width: 30%">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security<BR>
Type</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; width: 8%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Security</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Class</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Title</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; width: 5%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fee</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Calculation<BR>
    or Carry<BR>
    Forward<BR>
    Rule</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount<BR>
Registered</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed<BR>
Maximum<BR>
Offering<BR>
Price Per<BR>
Unit</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum<BR>
Aggregate<BR>
Offering<BR>
Price</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee<BR>
Rate</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of<BR>
Registration<BR>
Fee</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; width: 3%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carry<BR>
    Forward</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form<BR>
    Type</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; width: 3%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carry<BR>
    Forward<BR>
    File</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; width: 3%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carry<BR>
    Forward</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Initial<BR>
    Effective<BR>
    Date</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee<BR>
Previously<BR>
Paid In<BR>
Connection<BR>
with Unsold<BR>
Securities to<BR>
be Carried<BR>
Forward</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="13" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newly Registered Securities</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fees to Be</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Paid</P></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.001 par value per share</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,730,608 (1)&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.80(2)&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ $10,445,703(2)&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$110.20 per</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$1,000,000</P></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,151.12 </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fees</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Previously</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Paid</P></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="13" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carry Forward Securities</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carry</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Forward</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities</P></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Offering Amounts</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,445,703(2)&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,151.12&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Fees Previously Paid</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Fee Offsets</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Fee Due</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,151.12</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares of common stock will be offered for resale by the selling stockholders pursuant to the prospectus contained in the registration statement to which this exhibit is attached. The registration statement registers the resale of an aggregate of 3,730,608 shares of the registrant&rsquo;s common stock. Pursuant to Rule&nbsp;416 under the Securities Act of 1933, as amended, or the Securities Act, the shares of common stock being registered hereunder include such indeterminate number of shares of common stock as may be issuable upon stock splits, stock dividends, or other distribution, recapitalization or similar events. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This estimate is made pursuant to Rule&nbsp;457(c)&nbsp;of the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per share and maximum aggregate offering price are based upon the average of the high and low sales prices of the registrant&rsquo;s common stock on April&nbsp;10, 2023, as reported on The Nasdaq Global Market. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2312861d2_ex5-img002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2312861d2_ex5-img002.gif
M1TE&.#=A>P 0 '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M +#!-1HQQA0H\  5>*$$$6!$.S2RBRLXH *+J 48!%".  ],,P!WP,0,.B"
M*/"2"1M Q4?(H8-4<.0*_N*(.X:!#G?@ FOFR(4[W/&,87CT'>"XA3F<\0R-
MJ ,>&K%H/-[!C'-4@QB\B(<Y/#H,8;AC1M"HJ$@W<@YA+ ,7[W!'-J"QG'?D
JU!V[&(8MLI$+<FAD&[E8J3!L@8MLQ,,9--W%-(3A#*'>PJ.XR%5    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2312861d2_ex5-img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2312861d2_ex5-img001.jpg
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M(^O721K*8U+C=%M4@J3OC4.>>,;CQFI8M>N&FM!)' D<K;'(?<<ER@X!. <
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MQQ]5]:V*SM9NSIUO%>%RL$,H,X[%""OZ$@_A6.-4O;,BVN9LW,9\]MX^\LF
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H*\-I9^4[)OE(;:<9&WO73?9H'C :&,@@9!4=NGY5(45N&4'OR*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>lg_carismatherapeutics-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_carismatherapeutics-4c.jpg
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M -0  0 !! ,!               ( 0(&!P,$!0D! 0 " P$!
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MA+0"V](\;BJ1+=WLY C(YRG 0P^35Q6JU\;(=;]O^]>D(#K0\5J78*J00$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MEG1YZP;0.9=#U=P /M9HQ6OC(URFJDVI!;$ZN[/WR6VUE<&TS-/2QEWRMF)
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MTD+Q3$QO;VV^+HK$UAV \'@H67H" @(" H%H<TF@XH+E((" @(" @(" @("
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MZP9[8,\=G,Y^0VRX_C<=([6$=KX'.KR'[GX)]]3$JW6U3"V_G\3N/&09O#7
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MKFZZJ1<H!!:YP;Q4"T/ [$H+@X$T[5(N0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M=LF=OP XFZK';@BG"%AIY0]SE>C'Q-J6&)Q^*@^2XRT@L[=O"*WC;%&.[E#
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MH*A,I;^SGO-^>VM+@+Z3UE_@B(HRXU>ZU?\ O9J?M=6K)$L-T4;M:[F5E%R
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M-A8G XO V,6+P]I%98^ ?B[>)M&BG;4\7'M)J5*KU&AP-7=JE"] 0$! 0$!
M0$'', 8R#P4)0CZU;+;LS>]PRU9R8K* WMDT#E:SG=21@\CN'@5CEEB:PUUK
M3N\5"S9?0?<#L#U&L(2XLM<NUV/F;4ZN>*QD^1P5H5N36CXZ\5D87(@(" @(
M*'@43#0/M4_HU@?GK_BU2Y>Q%CM561G'2*_L\5O_ !N4R#Q%8V<=S/<2.X!C
M(G$^<\!XH3%8>)O+=-]O+<=]N&^<>:Z?2WBJ:1V[-(V-[J-1%L,KZ0]+KCJ)
MEW37?-!MG'N:Z_G%0Z9QU$,9[''[(]@\5,1M1=<F9CL;9XJR@Q]A#';65LP1
M06\6D;(V\ !]5>*R,3T0*(A5 0$! 0$! 0$! 0$!!\X\C_.=_P#.9_C7+#+T
M1N=91)&Y,_V=?HOQ_P"7N?C7++&YAEM965$! 0$! 0$'%+JS10()=6,X_/\
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M;K+;]DRV;)0S3$N?/*X<"^1WI'[W0#N4THK6K)HXRTU^QIP4H<J @(" @("
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MM1FUDSLM=EH^2VVS%^6DSU1N\M8;IM;.WL866UI%';V\0Y8X8FB.-C1V-
M"UTS,NEMLMMBEL4AV&\PKS4\*(LN+@.*@5KI52* U0545!2" @(" @(" @("
M @(" @XY?@5""-OM,;VD9':;%L9/W_EO<I0<8PX^JCU[W DT[E699+(JCAVD
M]I[2L;(OA@FNIH[:VC,MS,YK(8VCF+GN-&@ =YH@F_TIV!;[!VQ'CG-!R]X&
MSY:4T]*8CX ([& T&O>LD0Q735L("BE152" @(" @(" @(""A%>""C6\J"Y
M0$! 0$! 0$! 0$! 0$! 0$%KVEPT0:.]IG "^V7:YM@_C.(NFDT'^2G_ !;J
MGN&A597ME$W_ +%C9J.YB;V3&Y?'Y"(\K[6YAE#N[E>%*KZ'VLT=Q!%<1ZQS
M,;,S[UXJ/>66&!VD! 0$!!0\"B8: ]JC]&L#\]?\4JW+6(LJC*J"16A+000:
M=H/$*$O7VQMS([NS]EM_%L)N[V0-+P"6Q,&KY#3L:U3"NY.W:FVL;M'"6>W\
M4QK;2TCY>;0.DD.KGN[RXU62-C#,U9"I0(" @(" @(" @(" @("#YQY'^<[_
M .<W'QKEAEZ(W.JDD;DT/9U^B_'_ ):Y^-*R6[F&YM965$! 0$! 0$'#._U<
M3I*5Y 3[@0?.>^D=-?W<LA)>^>5Q<>VKW%8I>CH<'E]U0FB7_LUP1,Z;QSM;
M^-FO;QTSAQ);)RBGD HLEK#?.UN964$! 0$! 0$! 0$! 0$! 0$!!X^Z?T8S
M7S"Z^*>HE,/GCVK&]$1L5\R@2.]G'IRQS7;^RT59'$Q86)[= T>B^?4#4TY6
M>%>]7MABNE)*.+U9)"NQN5 0$! 0$! 0$!!QR_ U-"@B?[2^UF8W<EEN>UCY
M(<O&Z&ZI3_>;:FM =*L+1XD%4F&6V6CNU49%#2A^JO@B&^O9VZ;LRUZ[>V7A
M#K"R>8\3'(*MDG;7FE [1'\%OW7D5HACNE*=D1:>8E9&-RH" @(" @(" @(.
M.6I% @BY[3FUV6N3Q>[+9GHWS#9WKFC3UT(K&XGM)8>4?>JDLMLM :?K%59)
M9#L;,NV]O'"9EK^1EK>1&5W#\2]W)(/VCBHA$Q5/Z$M<T.;\&@/NK,P.=$"
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M9;<_N>7<E[$'V&##3 '<#>2?!-/N&U<K1"ETI<,86=OH@461B<J @(" @("
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M9.2=E]IX3*2$<]U96\SCXOC!/OA9(>>8VLB4H$! 0$! 0$! 0$! 0$! 0$!
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M1P%3V#Q4B<G1S;0VML+%V+QRWERSY==ZU)EN0'#3L(;RBBR0P7-A*51 0$!
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M0DACYFQ5^T#Z\?*2OIO([KKM+%>N7QK[CMMC6W4ZHKVMBK?.:$! 0$! 0$!
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M+):QWMNJS&(" @(" @(" @(" @H31!:9&#Q\B"WUS4%PD:>U!8^:.-I<X@,
M)<[L "#Q[K=^U+$D7V<L+=S?A"6Z@CI^W<%%4TEXUWU;Z;6@<)MRV+P-/Q,H
MG^*YDJGAE$?J[F\7N/J)F<SA;@76,N3;^HN '-#O5VT4;M'AIT<TC@L<LEL4
MAA*B%H2I]ED?^ULT?_OQ\2U6L8[][?BR,:CN"#C<*$]R@1FZR[7GPVY7YB*-
MQQV6_'-D ]%L]/383I2M.?SKYSSS1_"S<?1?Z7UO[9U\9M/\.9]NST=#6_#W
M_>7.71T2Z^)KM!JIZ*$GB>'8>*6T.A([H?M:7#X*;-7C#'=Y4M,3' @BVC'H
M'7[8DGR4*^A<@T<X<4WW12;_ $/DOW/KHSYXQVS6+/2VPNG<>(+''6A[E'2(
MZ>T1.U^>Q%L"*Q6KY"WM'K'T_P"ZMQH=SC>?S[=L>)IKL*V<;W*W))^SS&X;
M3R$A'HOR#VM/?RQ1U^NM+KOF>1W?(H_T3_<W M>Z$0$%":"J#B=Z0+FUKW))
M"./63J+<Y+(3[5Q$SF8NT<8K^2-Q!GF% YAH?@-X4[3Y%M])IXX>*7&\WYC,
MW_"LG=O\(GS-0<.':ME$1&YRU-M;9/*-.[O2AT[#7ZC]96K$1281Q3;VMX=%
MNH]P+J/:&;G=+'(.7%7#R2YKV@ 0DG7E('H=W#R:C5::(CCAU_*.973/PLDU
MGHG\&_VN'N#5:NKK5X[^]*BJ @(*'0(.C?WUKC+*XR%[((;.U8Z::5W ,8#7
MWE,179"E]\61-UVZ$3>H'4+)[WR#JO=;X.!Q^16(<:4'!\G8YY'[7@.];[3Z
M>++=VU\^YCS"[/?LFEL;F&U'U4_47KB:=#3\42K6GE[^U*1TI[7HX+/Y7;60
MBR>&N'6]S$=:'T'LJ"6O;P+=.U8KL-N2*2]&GU5^&:XYI3HZ)[4L]@[RL]ZX
M1F4@:(;QA]3>VH=4QS"E:#CRGB"N?S8IQW4?1]'J[=1CBZ-_2RT&JQ/8J@("
M#J9%G/873!Q,,@'G:4MWJW;I06#'1?BW?"9Z+O C1=3$[NQ\IOBEUT=KO8FY
M^196QNS2D%Q%)J*_!>"J7[;9CK9-+-,MLSUPG$QP<*C4'@? KF7U1R(+)"0T
MTX]B#HY2QBRF.N<=<#\5=Q/ADIJ U[2#W=ZP9L49;9LG=,49\&:<62V^-]LQ
M*'.:P]Y@,I=8B_:6SVDACJ= YH/HN'@X:KY-J=/=AR39=LI/F?==%J[-1AB^
MS;$QYW17FX>E[K=VQ3N\ HB.O<1,TW;7/:6ESD+N&QLF&6ZN7".&-NM7.T'U
MUDQ8IR71;;MF9[6'-GMPV3?=LB(JF!M+"MV[@,?AF&IM(6LDIJ#(27/(K3BY
MSE];TF",.*VSJCSOA.NU/U&>_)^:?,]]>MX1 0$! 0$! 0$! 0$!!QRLYV<O
MB@@#U!NC>[[W'='[/(3]WV#N3L\&K$SPQO7_  >^H2D'[*UD'9;<>0I7U=O#
M;5^_>7T[_L%:U2_<E"T$<5D8ER @(" @(" @(" @(" @(" @(" @(" @(+7.
M#14H*>L96E=4'#-=V]K"^:XD;%#&.:221P:QK>\N.@"#",UUBZ;8,.9=[@MY
MIA_DK+FO"3W5@#V@^4J)F%J,"ROM0[6@]'$XB]OG"HK,Z.UC)'<09#[K0J\2
MW"PS)>U%NN8N&*P]C9L/ SNEN7CR$.B'^*G$G@8CD.N_5#(!S?SU\EB<*<EM
M;P1Z>#N0O'[95F4Q;#&+[?>]<D"R^W%D9XS_ ))UU+R?M>;E]Y15;8\*:::X
M?SSR.FDX<TCB\^Z4-CC/;3CXE2G8KX:?K!054&NO"O8B%>]2B4Y>B/T5[7^9
M_P"T<LD,,M@*4" @(""AX%$PT#[5/Z-8+YZ[XHJER]B+"JR,PZ4?29M3^L(_
MP')"MR>HX+*Q2JB! 0$! 0$! 0$! 0$! 0$'SCR/\Y7_ ,ZG^-<L,O1&YUDD
MC<F?[.OT7X_\M<_&E9+=S#<VLK*B @(" @(" @M<">"#@= U\;HW .8X$.:1
MS AW&H[CW*$M ]2?9WMLB^7-;%,=C?N)?+B''U=M(3J3$X_O;C]J?1U^Q"B8
M7BZB-V6P^6P%[)C,U9S6-]#\*"X8Z-U#J" 1J#V$$U5%ZNDH#A^IXA$N_B,Y
MF,#<B]PM_<8^ZI0R6TCHR0. =RD<P\'54IF*MN;:]I3=>.#(=QV<&9@'&=G\
M4NN[X4;3&:#_ $8\JF+F.;6Y=L=>.G>X?502WYQ%ZZC?D^2;ZEM3_IFET5/O
MGA6JIPMEPW<$\+)H'MEAD ,<C"'-<#P((T*E%'-ZYG>I0N#ZNH@N0$! 0$!
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MK+CPWWSLAY-1K,6"/;F*]72T5N+KMN"^OX7X.)F/QEO*)#&X-DFG:P_!D-:
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M/<&,8P%Q<2:4 '$DZ:(BJ3O2?H'9V,,&X-\PMN<D_EDM\-(*P0@ZM,PX/?\
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MRZW#ALQ6\-D1$/5:*&N@KQ5>EF<BD$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MBQQ5&5RV]M)>W,%G"*RW$C(64XU>X-_54$[GT&VSAK?;V#Q^%M6!EO801P-
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M"B8?/IHH WC33W-%B>CH"A";?0J5TG3# <YKR1/8VNE&MD-!Y@LD,$MEJ51
M0$'C[I_1C-_,;KXERB4QO?/%8WHZ%5"(W)W](OHQVG_5T'X*RPP2S92@0$!
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M?<4HH<[3HI0J7M""GK&=Z!ZQJ!ZQG>@Q;=&_MH[2A<_/Y6&UE;J+7F]9</\
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MEGL]/>Z+/;^CH!22UP9/'M!N"*Z?Z,>?A0VB&.ZY)"&W9"QC(VMCB8P,8QH
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MV/\ :AW; &C)8BPNZ#5T7K;=Q/>:OD%?(%;B5X'MQ>U6*M]?M2E!0NCOP=?
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M.WMT[O%;:=[CH-"!W%$[Q$3TO5VUMS(;IS%OAL<PNFF=^,DI5D<0(YGN-"*
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M#)>[=D=@<@ZI,43?66CR?]$2WD_8$ ?:J)M7BZC1.YNBO4+;+GODQ;LE9M)
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M@1*K&<JB@O0%((" @(" @H15!5!3510*=RD *<2@J@(" @(*$506AI[4(5+
M36M!X(+?5CBH 1ZUJI%Q!(TI5  H@N0$% :H!-$%KG"FFO@$D:"]HF_K)@<6
M"=/77;AW4Y8QY_2*VN@C?/1N<G]P9(X;+>FM?P_%HPGW>'=]9;6>AR&_9"0_
MLZV!CPV8R=#RW-RR%I/^@:21_CA:;7S[<0[?D-E,-UW7+=BUKI!2" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @M=72G?VJ4!< /
MUE"5GK"32A!\4D'N%*\!KJJT$..HN/\ S9O?-V@T;\JDF;Y+C\<*> YJ+I=/
M=-UD5?,^96<.INKNF6,<""-3^JLU*UAK[9VUCH30V=EV9C;&(R)>'/GM8C+3
M_.!O*_\ Q@0N:RVS;=,/J6DR<>&V?%#(/6-KP*Q4>M4.!-.U$+E((" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(""UU=*4\ZF$2$\NI4)6.>"*:@DZ
M(+'R,C'I'E(J23Z(]U1MDF8A%?K3F&97?$\<,HEM["".V:6D.'.*O>:B@KZ0
MJM]I+)BS:^?\YS1DU%*Q,1'1X=C7FB]UV]HHG9-$I>BYQ]EL>PMV7$)NYW27
M%Q$R1KGASW\NK02:D-"Y_55F^9?1.4_#LT]ML3%>ULKG!;4$T.M1JO&W*K7A
MW#AQJI%Z @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @M>:!0,>W'O#;NU;;Y1F[UEN7"L<'PIY*?:L;J>/D[UEQX[K]T/+J-5BP16
M^Z(]+2FX^OV5N"^#;5FRS@U:VZN0))B.\,:>1I\O,MECT,5]J>YS.HY[=/RX
MIV_\M<93>V[LU49+-74S'_"B$KF14_)MHS_%7MMPV6UV0T5^OSW[[YB?%,T[
MG@DEQJXDN-:DFIJ223XK+$4>&Z^Z9K.V?'M*=^H-*A6G;-2?(]#'YW-8IXDQ
MF2N;-[=08)GQ'S\I *I=CMG?%6>S59;=D771V3+.L#UPWEBG-;D7QY:VTYFS
MCDEIX/81K]\UR\>3163NV>'8W.#G>7'2+O:CS^EN7:'5W:VZ7,M7RG'91^GR
M6Z(:UQ'8Q_P7>%:$]RUN337V=#IM-S3#FZ>&?'1L 2L\QI3SKS-JJ'M<:"M0
M@O0$! 0$! 0$! 0% *00$! 0$! 0$! 0$! 0$! 0$!!0FB@6&1H&M0I&/;FW
MGMW:5KZ_-WC87/!,5N/3GD(^T8-3Y>'BLEF.Z_=#RY]5BP16^Z(\5=K2&Y>O
M>;O2^#;5M'CK:I:RYF FN" ?M:EC2.[TEL\>AC?=/=_PY;4<^OG9CBD>./XM
M:Y7<F?SCR[+Y.YN^YDLKC&*_:MJ !X +W6X[+=T1W-#?J\U\UF^[_*:/*/'C
MYJK)$4>69F9K.\.M%,32JM=E)5:2PAS26O%"T@]HX>XJ<$=5>UEMONMW3,>5
ME6%ZE[VP+F_),Q--"VG\6O'?*(J#L],DM'WA:L5^FQW=#88>::C#.R>+^ZL_
MBV[M/KWB;Y[;?=5M^;+AU&B[@YI+:IXEP)YV>^M;DT4V[;=KI=+SS'D]G)[,
M^;TMP6U]:7MO'=64S+BVE =%-$YKXW ]H<TD'W5KYB8WNALOMNBMLUCQ.PV1
MKC05_41=>B! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M'@!HH3#4O4OJY:[;,N$V^676=IRSS&CH+:H[0#J\=C> [>X^_3Z6;]L[G/\
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M(" @(" @(" @("#CD#2T@BH)IYSH@BAU7V0[;&YR;"$G%Y4F:R8P$\LA/IQ
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MDE],M([VUH?(OJW+L$X<%ML[Z/A?--3]1J;[XFL5I'9#+%LFJ$! 0$! 0$!
M0$! 0$! 42+'LYVT2!B&2Z9;*RU]<9/(XIDU]=/Y[B;GE#G.H&@D!]. [EFL
MS7VQ2)>3)H\.2:W6Q,]C@_N@Z>?T,S_62_NU?ZC)UL7[=I_R1W0?W0=/*?S*
MSSR2_NU$ZC)UG[=I_P D=T,"ZN[!VEMO9D^3PV-;:7S;BVC;,U[W.Y7R .%"
MXC4>"].ERWS?$3+5\ST>#%IYNMMB)CQ-*;?MH+S/8JSN6"2WN+J**5G %CG
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MN8NC6:^F?,X5)Y0XU:T$]C1H%TEEG#%(ZGS'/E^+ENOG^:71:USW!K 2XD
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MUUA\]YS]R?&LG%@K$3ON]5)W2W:QM#7PUU78PX-RJ4" @(" @(" @(" @("
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M U(T"USI*.12*'B$0M>TN;R]JBB:NA^:; WS<E\FC&0:PQ"Y#&^M]6ZCN7F
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M#^?\5\\A_#"W>6/]<N&TD?[L>W^9.!K@= =5S3ZBN0$!!0N XH <#P050$!
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M;M;'#FN/HG6E1W>5>5MW(/-7MHI1"JA(@(" @(" @(" @(" @(" @(" @("
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M>^/Y?,VN/F&"_=='?#+62QO8',/.TCT7-((H>XC18IBCW1,2Y&O#N"JE<I!
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MB7SR+)N]F-LRRH=,M^U(_,-V2.)#1]>J\T:FSK;*.69X_EGNGU*_W8[_ /\
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MRLCV9G7O-&_(YAYW,('OE9<.V^'DUDTPW3/4A:[]Y=]X>'D73;GRZZ*UA.+
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M75UHH2JI! 0$!1(T9[27\V;;^>S?$/6UT&^[L_%R7W)[F+^^?_C<UATJ^D/
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M%4^KY+9W+V<P,@_57GU]*6^5LOMZ=N3_ /G\4@%JG7B @(" @(" @(" @("
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M=QEMB,7$(;*V8&,;]EKJ7.--7.)J2M!=?-TUE]$PX+<-D66QLA["JS" @("
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M"0TUI7G"]E^LXK9AH\')/AY+;JUX9KX;&]?5\23Z2UL.HE>. \@4H7(D0$!
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MD.S<$/\ )G?NT^N\2?V#^KP[C_IRO_\ F"'^3._A$^N\2?V'^KP[C_ISOO\
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M(" @(+7 EM!Q04+2::C3BA55S>9-HM]7YCWA0+FMY?(@J0#Q4@6U-:HA5$B
M@(" @(" @(+7"O;1 #> [ @-%*U07(" @(" @(""A&FB"UK2"236O>@O0$!
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M1/@O'J<]N2(B&\Y3H,FFNNF^FUNE:]T0@(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M(4(=_@1(UI""X5[4%4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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4 @(" @(" @(" @(" @(" @(/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
